SCHEMBL427847

SCHEMBL427847

CC1(C)COCN1C(=O)n1cnc(-c2ccc[n+]([O-])c2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.54
CES2 O00748 1/20 0.54
HSP90AA1 P07900 1/20 0.34
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 3/20 0.34
GAA P10253 3/20 0.34
CYP1A2 P05177 2/20 0.34
HPGD P15428 2/20 0.34
HSD17B10 Q99714 2/20 0.34
GLA P06280 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
CYP2C9 P11712 1/20 0.34
TSHR P16473 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
POLB P06746 1/20 0.33
CYP2C19 P33261 1/20 0.33
RAB9A P51151 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
CNR2 P34972 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425743 0.85 FAAH (0.43) FAAHCES2KDM4EALDH1A1GAA
SCHEMBL427485 0.81 FAAH (0.38) FAAHCES2KDM4EALDH1A1GAA
SCHEMBL7898244 0.81 KMO (0.38) FAAHCES2KDM4EALDH1A1GAA
SCHEMBL425714 0.81 CYP2A6 (0.46) HSP90AA1HPGDCYP2C9CYP2C19LOXL2
SCHEMBL427643 0.81 HSD17B1 (0.37) KDM4EALDH1A1GAACYP1A2HPGD
SCHEMBL427535 0.79 CNR2 (0.35) FAAHCES2KDM4EALDH1A1GAA
SCHEMBL427118 0.78 DPP4 (0.40) FAAHKDM4EALDH1A1GAACYP1A2
SCHEMBL427956 0.78 TP53 (0.39) KDM4EALDH1A1GAAHPGDSMN1; SMN2
SCHEMBL464499 0.78 NR4A2 (0.34) FAAHCES2KDM4EALDH1A1GAA
SCHEMBL427770 0.78 FYN (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885CES2 62/4885HSP90AA1 1590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.